Phathom Pharmaceuticals, Inc. (PHAT) closed the last trading session at $10.95, gaining 21% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.5 indicates an 87.2% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $8.02. While the lowest estimate of $5.00 indicates a 54.3% decline from the current price level, the most optimis ...

Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 7.4% over the past four weeks to close the last trading session at $12.98, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $16.3 indicates a potential upside of 25.6%. The mean estimate comprises four short-term price targets with a standard deviation of $2.15. While the lowest estimate of $14.20 indicates a 9.4% increase ...

Group 1 - MongoDB (MDB) shares have increased by 10.5% over the past four weeks, closing at $209.2, with a mean price target of $280.88 indicating a potential upside of 34.3% [1] - The mean estimate is based on 33 short-term price targets with a standard deviation of $54.3, where the lowest estimate is $170.00 (indicating an 18.7% decline) and the highest is $430.00 (indicating a 105.5% increase) [2] - Analysts show strong agreement on MDB's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Over the last 30 days, 11 earnings estimates for MDB have been revised higher, with no negative revisions, leading to a 15.8% increase in the Zacks Consensus Estimate [12] - MDB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Kimbell Royalty (KRP) shows potential for further upside, with a mean price target of $18.6 indicating a 27.3% upside from its current price of $14.61, following an 11.7% gain over the past four weeks [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $4.98, indicating variability among analysts; the lowest estimate is $12.00 (17.9% decline), while the highest is $24.00 (64.3% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, although it does not guarantee the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about KRP's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 34.1%, with one estimate moving higher and no negative revisions [12] - KRP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can mislead; empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) has seen a significant stock price increase of 44.1% over the past four weeks, closing at $8.17, with analysts suggesting a potential upside to a mean price target of $18.90, indicating a 131.3% increase from the current price [1] Price Targets and Analyst Consensus - The average price target from analysts ranges from a low of $12 to a high of $25, with a standard deviation of $4.04, suggesting a potential increase of 46.9% to 206% from the current price level [2] - A low standard deviation indicates a strong agreement among analysts regarding the price targets, which can be a useful indicator for further research [2][9] Earnings Estimates and Market Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, five estimates for ORIC have increased, leading to a 12.6% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - ORIC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]